GleamWall
中文EN

IMTX Immatics N.V. IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1809196 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-1,390.9%
TTM EPS YoY-1,250.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.1%
ROA-31.2%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets13.9%
Debt / equity0.00x
Current ratio11.72x
Interest coverage-192.41x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q2*2025-06-302024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q2*2023-06-302022Q2*2022-06-302021Q22021-06-30
Income statement
Revenue————————
R&D expense45.11M——35.22M—27.32M25.22M20.34M
SG&A expense12.78M——10.13M—9.36M8.68M8.27M
Operating income-53.13M——-26.56M—-14.31M-16.66M-23.40M
Interest expense244,000——226,000—206,000376,000140,000
Pretax income-71.35M43.27M-2.35M-17.85M-1.72M-24.61M-12.84M-26.53M
Income tax-1.00M2.52M2.95M140,000518,00001.15M0
Net income-70.35M40.76M-5.30M-17.99M-2.24M-24.61M-13.98M-26.53M
EPS (basic)-0.58—-0.05-0.17-0.02-0.32-0.22-0.42
EPS (diluted)-0.58—-0.08-0.17-0.03-0.32-0.22-0.42
Weighted avg. shares (diluted)121.55M—110.30M103.07M105.93M77.31M64.92M62.91M
Balance sheet
Cash & equivalents256.63M236.75M189.20M158.14M122.09M130.41M265.12M160.09M
Receivables1.96M5.86M—2.81M—330,000961,000718,000
Current assets503.94M629.55M—559.12M—364.62M336.02M198.34M
PP&E, netmay include right-of-use assets (IFRS)46.31M50.38M—50.29M—27.19M11.27M8.75M
Intangibles1.60M1.63M—1.61M—1.66M1.31M1.26M
Total assets567.30M696.15M577.23M626.97M653.12M410.19M368.30M216.50M
Current liabilities57.25M67.99M128.91M149.55M149.10M124.31M113.99M93.93M
Total liabilities102.73M121.30M198.06M245.70M258.99M191.98M243.36M160.87M
Shareholders' equity464.57M574.84M379.17M381.26M394.13M218.21M124.94M55.63M
Cash flow statement
Operating cash flow—-58.48M-33.73M-33.22M-32.60M———
Investing cash flow—-47.41M67.01M69.83M-241.82M———
Financing cash flow—146.36M-753,000-566,000174.65M———
Stock-based compensation4.14M——4.31M—5.51M-5.56M7.96M

Free plan shows the latest 8 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.